B+
Bull case
25%
Probability
Target price
$95.00
+40.0% vs current
WGS
GeneDxDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-08-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$72.00
+6.1% vs current
B-
Bear case
25%
Probability
Target price
$42.00
-38.1% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+28.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
+28.0
Positive
Sentiment proxy
+51.6
Score
AI commentary
News tone is mixed-to-negative after the Q1 guidance reset, despite strong testing-volume growth. Social, options, short-interest, employee-review, and post-print analyst-revision data were unavailable in the packet; missing coverage is not treated as positive evidence.
RankAlpha Sentiment Codex - 2026-07-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-15eventQ2 volume and margin checkpointHigh impact
The key event is confirmation of approximately 30,000 exome/genome tests, roughly $110-$112 million revenue, and approximately 70% adjusted gross margin under the revised outlook. [#SEC-8K-2026-05-04]
2026-10-15catalystPost-reset execution testHigh impact
Q1 exome/genome volume grew 34% year over year, but management reduced 2026 revenue guidance to $475-$490 million from $540-$555 million and guided to an adjusted Q2 loss of approximately $5 million. Delivery against the reset would support stabilization. [#SEC-8K-2026-05-04]
2027-07-17catalystVolume-to-profitability conversionHigh impact
Management still targets at least 30% full-year exome/genome volume growth, approximately 70% adjusted gross margin, and positive adjusted net income, but the Q1 loss makes conversion into profitable growth execution-dependent. [#SEC-8K-2026-05-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology